DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) Fundamental Analysis & Valuation

EPA:ALDMS • FR0012202497

Current stock price

1.34 EUR
-0.02 (-1.83%)
Last:

This ALDMS.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ALDMS.PA Profitability Analysis

1.1 Basic Checks

  • In the past year ALDMS has reported negative net income.
  • ALDMS had a positive operating cash flow in the past year.
  • ALDMS had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: ALDMS reported negative operating cash flow in multiple years.
ALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFALDMS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

1.2 Ratios

  • ALDMS has a worse Return On Assets (-2.92%) than 64.52% of its industry peers.
  • ALDMS's Return On Equity of -13.33% is on the low side compared to the rest of the industry. ALDMS is outperformed by 67.74% of its industry peers.
Industry RankSector Rank
ROA -2.92%
ROE -13.33%
ROIC N/A
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ALDMS.PA Yearly ROA, ROE, ROICALDMS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

  • With a Gross Margin value of 39.79%, ALDMS is not doing good in the industry: 80.65% of the companies in the same industry are doing better.
  • ALDMS's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ALDMS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.79%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
ALDMS.PA Yearly Profit, Operating, Gross MarginsALDMS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ALDMS.PA Health Analysis

2.1 Basic Checks

  • ALDMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ALDMS has more shares outstanding
  • Compared to 5 years ago, ALDMS has more shares outstanding
  • Compared to 1 year ago, ALDMS has an improved debt to assets ratio.
ALDMS.PA Yearly Shares OutstandingALDMS.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ALDMS.PA Yearly Total Debt VS Total AssetsALDMS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of 1.03, we must say that ALDMS is in the distress zone and has some risk of bankruptcy.
  • ALDMS has a Altman-Z score of 1.03. This is in the lower half of the industry: ALDMS underperforms 69.35% of its industry peers.
  • The Debt to FCF ratio of ALDMS is 7.73, which is on the high side as it means it would take ALDMS, 7.73 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 7.73, ALDMS perfoms like the industry average, outperforming 48.39% of the companies in the same industry.
  • A Debt/Equity ratio of 0.79 indicates that ALDMS is somewhat dependend on debt financing.
  • ALDMS's Debt to Equity ratio of 0.79 is on the low side compared to the rest of the industry. ALDMS is outperformed by 74.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 7.73
Altman-Z 1.03
ROIC/WACCN/A
WACC6.86%
ALDMS.PA Yearly LT Debt VS Equity VS FCFALDMS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M 20M

2.3 Liquidity

  • ALDMS has a Current Ratio of 1.16. This is a normal value and indicates that ALDMS is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.16, ALDMS is not doing good in the industry: 67.74% of the companies in the same industry are doing better.
  • ALDMS has a Quick Ratio of 1.16. This is a bad value and indicates that ALDMS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.62, ALDMS is doing worse than 82.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 0.62
ALDMS.PA Yearly Current Assets VS Current LiabilitesALDMS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ALDMS.PA Growth Analysis

3.1 Past

  • ALDMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 86.92%, which is quite impressive.
  • ALDMS shows a small growth in Revenue. In the last year, the Revenue has grown by 5.79%.
  • ALDMS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.24% yearly.
EPS 1Y (TTM)86.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.18%
Revenue 1Y (TTM)5.79%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%3.07%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • Based on estimates for the next years, ALDMS will show a quite strong growth in Revenue. The Revenue will grow by 13.02% on average per year.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year6.61%
Revenue Next 2Y10.49%
Revenue Next 3Y11.49%
Revenue Next 5Y13.02%

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDMS.PA Yearly Revenue VS EstimatesALDMS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
ALDMS.PA Yearly EPS VS EstimatesALDMS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2023 2025 2026 2027 0 0.05 -0.05 -0.1 -0.15

More info and screens

Find the best growth stocksShow best growing peers

2

4. ALDMS.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • ALDMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALDMS is valuated quite expensively with a Price/Forward Earnings ratio of 32.52.
  • ALDMS's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALDMS is more expensive than 62.90% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of ALDMS to the average of the S&P500 Index (22.19), we can say ALDMS is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 32.52
ALDMS.PA Price Earnings VS Forward Price EarningsALDMS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, ALDMS is valued cheaply inside the industry as 85.48% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.27
EV/EBITDA N/A
ALDMS.PA Per share dataALDMS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALDMS.PA Dividend Analysis

5.1 Amount

  • ALDMS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALDMS.PA Fundamentals: All Metrics, Ratios and Statistics

DIAGNOSTIC MEDICAL SYSTEMS

EPA:ALDMS (3/27/2026, 7:00:00 PM)

1.34

-0.02 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners6.3%
Inst Owner ChangeN/A
Ins Owners3.37%
Ins Owner ChangeN/A
Market Cap35.71M
Revenue(TTM)46.77M
Net Income(TTM)-1.67M
Analysts86
Price Target2.14 (59.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.28%
Revenue NY rev (3m)-6.28%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.52
P/S 0.76
P/FCF 14.27
P/OCF 14.27
P/B 2.85
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)0.04
Fwd EY3.07%
FCF(TTM)0.09
FCFY7.01%
OCF(TTM)0.09
OCFY7.01%
SpS1.76
BVpS0.47
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.92%
ROE -13.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.79%
FCFM 5.35%
ROA(3y)-9.22%
ROA(5y)-9.28%
ROE(3y)-35.31%
ROE(5y)-31.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.05%
GM growth 5Y2.79%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 7.73
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.16
Quick Ratio 0.62
Altman-Z 1.03
F-Score5
WACC6.86%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)86.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.79%
Revenue growth 3Y7.62%
Revenue growth 5Y8.24%
Sales Q2Q%3.07%
Revenue Next Year6.61%
Revenue Next 2Y10.49%
Revenue Next 3Y11.49%
Revenue Next 5Y13.02%
EBIT growth 1Y88.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year900%
EBIT Next 3Y166.84%
EBIT Next 5Y101.77%
FCF growth 1Y768.75%
FCF growth 3YN/A
FCF growth 5Y58.15%
OCF growth 1Y768.75%
OCF growth 3YN/A
OCF growth 5Y58.15%

DIAGNOSTIC MEDICAL SYSTEMS / ALDMS.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for DIAGNOSTIC MEDICAL SYSTEMS?

ChartMill assigns a fundamental rating of 2 / 10 to ALDMS.PA.


Can you provide the valuation status for DIAGNOSTIC MEDICAL SYSTEMS?

ChartMill assigns a valuation rating of 2 / 10 to DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA). This can be considered as Overvalued.


What is the profitability of ALDMS stock?

DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) has a profitability rating of 1 / 10.


How financially healthy is DIAGNOSTIC MEDICAL SYSTEMS?

The financial health rating of DIAGNOSTIC MEDICAL SYSTEMS (ALDMS.PA) is 2 / 10.